Great Basin Scientific (NASDAQ: GBSN) and Bio-Rad Laboratories (NYSE:BIO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.


This table compares Great Basin Scientific and Bio-Rad Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Great Basin Scientific 2,588.36% N/A 168.06%
Bio-Rad Laboratories 0.73% 3.15% 2.13%

Insider & Institutional Ownership

62.8% of Bio-Rad Laboratories shares are held by institutional investors. 28.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Great Basin Scientific and Bio-Rad Laboratories’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Great Basin Scientific $3.15 million 0.05 -$30.80 million N/A N/A
Bio-Rad Laboratories $2.08 billion 3.18 $233.59 million $0.50 445.66

Bio-Rad Laboratories has higher revenue and earnings than Great Basin Scientific.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Great Basin Scientific and Bio-Rad Laboratories, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Great Basin Scientific 0 0 0 0 N/A
Bio-Rad Laboratories 0 0 4 0 3.00

Bio-Rad Laboratories has a consensus price target of $240.00, indicating a potential upside of 7.71%. Given Bio-Rad Laboratories’ higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Great Basin Scientific.

Risk & Volatility

Great Basin Scientific has a beta of 5.09, suggesting that its stock price is 409% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.


Bio-Rad Laboratories beats Great Basin Scientific on 8 of the 11 factors compared between the two stocks.

Great Basin Scientific Company Profile

Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Receive News & Stock Ratings for Great Basin Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Great Basin Scientific Inc and related stocks with our FREE daily email newsletter.